HIGH QUALITY SERVICE

high technology innovation , high speed development.

HIGH QUALITY SERVICE

人類腫瘤晶片

上海芯超生物科技有限公司
生物芯片上海國家工程研究中心

上海芯超生物成立於2003年，總公司位於上海張江高科。芯超生物致力於臨床樣本標準化建設，建立了較大規模、高質量、臨床病理資料的以腫瘤為主的國際水準的組織生物樣本庫，具有國際水準的組織生物樣本收集、運輸、貯存的標準化流程，質量控制體系，安全監控系統與信息化管理系統。

同時，公司建立了一系列高通量基因組學、轉錄組學、蛋白組學、細胞功能研究等一站式研究平台。建立了大量診斷標記物、藥物靶點快速驗證/篩選的高通量組織芯片產品規模化生產的標準化流程與質量控制體系。依托於該體系，芯超生物服務於各大高校、研究所及醫院，為廣大臨床研究和基礎研究客戶提供以“以患者為中心”的學科建設整體解決方案。

商品介紹

★ 商品種類繁多, 請來電洽詢

另有各式組織, 檢體可供研究使用（FFPE samples, frozen samples and biofluids）

以下僅供參考

 

Catalog Organ Diameter Dots Cases Description
HBlaU060CS01 bladder 2.0mm 60 33 urothelial carcinoma 33 cases：27 case 1 core/case (tumor and NAT)，6 cases tumor 1 core/case. Clinical stage AJCC 7.0 1~4. Cases fromOD-CT-UrBla03-002
HBlaU066Su01 bladder 2.0mm 66 46 urothelial carcinoma(56 cases) with survival information：46 cases,tumor 1 core/case,  10 cases 1 core/case(tumor and NAT). Clinical stage(AJCC 7.0):Ois 1 2 3 4 stage.Surgery date: 2007.5－2011.11， visit date 2014.3 (follow up 2.3－7). Cases from HBla-Uro105Sur-01
HBra-Gli060PG-01 brain 2.0mm 60 60 1. Neuroglioma (57 cases, astroma and glioblastoma),3 cases normal of normal brain,1 core/case.
2.15 cases with survival information.
3. most overlapped with HBra-Gli065PG-01.
BreD060CS05 breast 2.0mm 60 34 34 cases of  breast cancer (most of invasive ductal carcinoma：tumor/NAT 1 core/case (26 cases)，tumor 1  core/case (8 cases)。 Clinical stage 0~3 (Version 6.0). 
HBreD030CS01 breast 2.0mm 30 30 30 cases of  breast cancer (most of invasive ductal carcinoma)： tumor 1  core/case  Clinical stage 1,2,4 (Version 6.0). 
HBreD030PG01 breast 2.0mm 30 30 30 cases of  breast cancer (most of invasive ductal carcinoma)： tumor 1  core/case .Pathology grade  I-Ⅲ.  
OD-CT-RpUtr03-004 cervix 2.0mm 62 31 1. Cervical squamous cell carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   
2. Clinical stage I.  TNM detail information. 
OD-CT-RpUtr03-005 cervix 2.0mm 62 31 1. Cervical squamous cell carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   
2. Pathology grade 2.
OD-CT-RpUtr03-006 cervix 2.0mm 62 31 1. Cervical squamous cell carcinoma (31 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   
2. Pathology grade 3.
HColA030PG02 colon 2.0mm 60 30 colon adenocarcinoma 30 cases: 1 core/case, grade I-Ⅲ.
HColA030PG03 colon 2.0mm 30 15 1.Colonic adenocarcinoma (15 cases),  tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   Pathology grade 2.
2.Reproduce of HCol-Ade030PG-01
HDgS-C140PT-01 digestive system 1.5mm 140 67 1. 6 types of digestive system tumor, 10 cases / type. Tumor and normal adjacent tissue. Esophagus squamous cell carcinoma, gastric adenocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, hepatocellcular carcinoma, pancreas adenocarcinoma.
2. 6 types of normal tissue,  2-5 cases / type, coming from 7 cases. Containing esophagus, stomach, colon, rectum, liver, pancreas.
HDgS-GIST060CS-01 digestive system 1.5mm 60 60 1. Gastrointestinal stromal tumor. 60 cases. From stomach, intestine. Tumor, 1 core/case.
HDgS-GIST090Loc-01 digestive system 1.5mm 90 90 1. Gastrointestinal stromal tumor, 90 cases. From stomach, esophagus, small intestine, large intestine, mesenteria, cavitas pelvis. Tumor, 1 core/case.
OD-CT-Dg03-002 digestive system 2.0mm 62 31 1. Multiple oragn (digestive system, 6 types) tumor tissue array  
2. Esophagas (5 cases), stomach (5 cases), colon (5 cases), rectum (5 cases), liver (5 cases), pancreas (6 cases).
3. Tumor (1 core/case) and matched normal adjacent tissue (1 core/case).
HEsoC050PT01 esophagus 2.0mm 50 29 29 cases of esophagus squamous cell carcinoma（21 cases tumor with matched NAT, 1 core/case; 8 cases tumor tissue 1 core/case):squamous cell carcinomas,basal cell squamous carcinoma,  spindle cell squamous carcinoma,adenocarcinoma,  adenosquamous carconoma,undifferentiated carcinoma.
HEsoS030PG02 esophagus 2.0mm 60 30 esophagus squamous cell carcinoma 30 cases: 1 core/case, grade I-Ⅲ.
HEsoS030PG03 esophagus 2.0mm 30 15 1.Esophagus squamous cell carcinoma (15 cases),  tumor (1 core/case) and matched normal adjacent tissue (1 core/case).   Pathology grade 2.
2.Reproduce of HEso-Squ030PG-01
OD-CT-UrKid04-001 kidney 1.5mm 85 40 1. Kidney clear cell carcinoma (40 cases), 2 cores/case. Normal adjacent tissue (5 cases), 1 core/case. 
2. Clinical stage I, II, III (Version 7.0).  
3. Pathology Grade 1, 2, 3.
HRaU-Uro120Sur-01 kidney pelvis and ureter 1.5mm 120 120 1. Kidney pelivis carcinoma and ureter carcinoma, 120cases. Tumor, 1 core/case  
2. Survival information available. Being followed up for 0.5-7 years.
HLin-Ade075Met-01 large intestine 2.0mm 75 32 1. Carcinoma of large intestine, 14 cases have primary tissue, normal adjacent tissue and metastasis tissue, 14 cases have primary tissue and metastasis tissue, 4 cases have metstasis tissue.
HLin-Ade147Lym-01 large intestine 1.5mm 147 49 1. Colon adenocarcinoma (24 cases) and rectum adenocarcinoma (25 cases), tumor (1 core/case), matched normal adjacent tissue (1 core/case) and lymph nodes (1 core/case).  
2. Clinical Stage N0 (12 cases), N1a (5 cases), N1b (5 cases), N2a (9 cases), N2b (18 cases) (Version7.0).
OD-CT-RsLug04-004 lung 1.5mm 106 53 1. Lung squamous cell carcinoma,  51 cases have tumor (1 core/case) and matched normal adjacent tissue (1 core/case), 1 case has tumor tissue (2 cores).  
2. Lung adenosquamous carcinoma (1 case), 1 core/case.  
3. Information of smoking history available.
4. Pathology grade 2.
OD-CT-RsLug04-005 lung 1.5mm 85 42 1. Non-small cell lung carcinoma (40 cases), containing squamous cell carcinoma (21 cases), lung adenocarcinoma (17 cases), adenosquamous carcinoma (2 cases), 2 cores/case.   
2. Normal adjacent tissue (5 cases), 1 core/case. 
3.TNM score available. 
4. Pathology grade 1, 2, 3.
OD-CT-LyMly02-001 lymphoma 2.0mm 30 30 1. Diffuse large B-cell lymphoma (30 cases), 1 core/case.
HOrg-C110PT-01 multiple organ 1.5mm 110 69 1. Multiple organ (12 types) tumor and normal adjacent tissue array. 3-8 cases/type.
2. Glioma (without normal adjacent tissue), larynx squamous cell carcnioma, thyroid gland papillary carcinoma, kidney pelvis uroepithelium carcinoma (without normal adjacent tissue), ureter uroepithelium carcinoma, bladder uroepithelium carcinoma,  cervix uteri squamous cell carcinoma,  endometrioid adenocarcinoma (partly without normal adjacent tissue),  ovary adenocarcinoma (without normal adjacent tissue), penis squamous cell carcinoma, seminoma of testis, prostate carcinoma (without normal adjacent tissue). 
HBreD075Bc01 Breast 2.0mm 75 75 1. Breast invasive ductal carcinoma (75 cases), 1 core/case. 
2. Clinical stage I, II, III (Version 7.0). 
3. ER-, PR-, Her2-  information available
HBreD090Bc01 Breast 2.0mm 90 90 1. Breast invasive ductal carcinoma (90 cases), 1 core/case. 
2. Pathology grade I, II, III 
3. ER-, PR-, Her2-  information available
HBreD145Su01 breast 1.5mm 145 145 1. Breast cancer 145 cases. 1 core/case.
2. Clinical Stage I, II, III (Version 6.0).
3. Surgery date 2001.1－2004.8, visit date 2013.7. Being followed up for 9-12 years.
4. 138 cases overlapped with HBre-Duc150Sur-01
HBreD145Su02 breast 1.5mm 145 145 1. Breast cancer 150 cases. 1 core/case.
2. Clinical Stage 0,I, II, III (Version 6.0).
3. Surgery date 2004.8－2008.12, visit date 2014.7 . Being followed up for 5.6~10 years.
4.141 cases overlapped with HBre-Duc150Sur-02